enGene Therapeutics (ENGN) Common Equity (2022 - 2026)
enGene Therapeutics' Common Equity was $230.29 million in fiscal Q3 2026 (quarter ended Jul 31, 2026), up 14.8% from $200.67 million a year earlier but down 9.7% from the prior quarter.
Powered by 
Analysis
enGene Therapeutics (ENGN) Common Equity (2022 - 2026) Analysis & Trends
At the end of FY2025 (ended Oct 31, 2025), Common Equity at enGene Therapeutics came in at $167.71 million, down 38.5% from FY2024.
- In earlier fiscal years, Common Equity was $272.61 million in FY2024 (+276.1%), $72.49 million in FY2023 and -$76.61 million in FY2022.
- Quarterly Common Equity has moved between -$93.92 million (fiscal Q3 2023) and $281.55 million (fiscal Q1 2026) over five years.
- Compared with a year earlier, Common Equity has increased for three straight quarters, with growth averaging 69.8% over the last eight quarters.
- The best year-over-year quarter for Common Equity over five years was fiscal Q1 2025 (growth of 300.7%); the worst was fiscal Q4 2025 (a decline of 38.5%).
- Per Business Quant data, ENGN's Common Equity in the three fiscal quarters before Q3 2026 was $255.17 million (Q2 2026), $281.55 million (Q1 2026) and $167.71 million (Q4 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,140.19 Bn | 1,108.77 Bn | 19.71 Bn | 33.88 Bn |
| 2 | Johnson & Johnson | 634.59 Bn | 554.45 Bn | 17.30 Bn | 81.53 Bn |
| 3 | AbbVie | 499.62 Bn | 472.73 Bn | 12.70 Bn | -5.94 Bn |
| 4 | Merck | 354.90 Bn | 309.28 Bn | 12.21 Bn | 41.98 Bn |
| 5 | Novartis Ag | 300.00 Bn | 263.99 Bn | 11.24 Bn | 41.95 Bn |
| 6 | Astrazeneca | 263.32 Bn | 237.01 Bn | 12.86 Bn | 50.37 Bn |
| 7 | Amgen | 238.09 Bn | 193.49 Bn | 7.24 Bn | 11.69 Bn |
| 8 | Gilead Sciences | 193.99 Bn | 168.19 Bn | 6.22 Bn | 11.83 Bn |
| 9 | Pfizer | 170.34 Bn | 116.99 Bn | 10.94 Bn | 85.49 Bn |
| 10 | enGene Therapeutics | 107.74 Mn | -886.73 Mn | - | 230.29 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 31, 2026 | 230.29 Mn |
| Apr 30, 2026 | 255.17 Mn |
| Jan 31, 2026 | 281.55 Mn |
| Oct 31, 2025 | 167.71 Mn |
| Jul 31, 2025 | 200.67 Mn |
| Apr 30, 2025 | 227.29 Mn |
| Jan 31, 2025 | 249.95 Mn |
| Oct 31, 2024 | 272.61 Mn |
| Jul 31, 2024 | 230.33 Mn |
| Apr 30, 2024 | 242.97 Mn |
| Jan 31, 2024 | 62.39 Mn |
| Oct 31, 2023 | 72.49 Mn |
| Jul 31, 2023 | -93.92 Mn |
| Apr 30, 2023 | -89.24 Mn |
| Jan 31, 2023 | -84.01 Mn |
| Oct 31, 2022 | -76.61 Mn |
API Access
enGene Therapeutics Common Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=common-equity&ticker=ENGN&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "common-equity", "ticker": "ENGN", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=common-equity&ticker=ENGN&period=max&api_key=YOUR_API_KEY");
const data = await res.json();